Individualized everolimus treatment for tuberous sclerosis-related angiomyolipoma promotes treatment adherence and response.

Noelle K X ChungPeter MetherallJanet A McCormickRoslyn J SimmsAlbert Chee Meng Ong

Published in: Clinical kidney journal (2022)

In this cohort, everolimus promoted AML regression in all patients who tolerated the drug for >6 months with stabilization observed over 3 years. Trough levels enabled individual dose titration to maximize responsiveness and minimize side effects. The use of 3D MRI assessment of lesion volume was superior to 2D measurements of lesion diameter in monitoring treatment response.

Keyphrases

magnetic resonance imaging
emergency department
metabolic syndrome
type diabetes
computed tomography
renal cell carcinoma
acute lymphoblastic leukemia
skeletal muscle
weight loss
replacement therapy
adverse drug